Company | Name | Exchange | Sector | Industry | 3 Month | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fengyinhe Holdings | Hong Kong | Financial | Investment Banking & Investment Services | 117.5% | HK$295.12M | 0.9x | -0.19 | HK$0.87 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Everest Med | Hong Kong | Healthcare | Pharmaceuticals | 79.4% | HK$2.44B | -6.2x | HK$38.85 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
China Investment and Finance | Hong Kong | Financial | Investment Banking & Investment Services | 74.5% | HK$330.08M | -19.5x | -0.29 | HK$0.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
OSL | Hong Kong | Technology | Financial Technology (Fintech) & Infrastructure | 68.7% | HK$4.82B | -21.4x | -0.59 | HK$7.68 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -15.8% Downside | Upgrade to Pro+ | |
Dynamic | Hong Kong | Real Estate | Real Estate Operations | 29.9% | HK$2.42B | 0.4x | 0 | HK$10.20 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbisko Cayman | Hong Kong | Healthcare | Biotechnology & Medical Research | 28.7% | HK$2.76B | -180x | -1.65 | HK$4.21 | -4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Orient Securities Int | Hong Kong | Financial | Banking Services | 0% | HK$19.49M | 6.9x | 0.02 | HK$0.19 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sunwah Kingsway Capital | Hong Kong | Financial | Investment Banking & Investment Services | -1.3% | HK$171.98M | -3x | -0.11 | HK$0.23 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Yinsheng Digifavor | Hong Kong | Technology | Telecommunications Services | -1.7% | HK$1.15B | 29x | 0.16 | HK$2.75 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sands China | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -4% | HK$146B | 17.6x | 0.07 | HK$18.02 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.4% Upside | Upgrade to Pro+ | |
Ascentage Pharma | Hong Kong | Healthcare | Biotechnology & Medical Research | -5.7% | HK$12.52B | -30.5x | -0.52 | HK$38.80 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.6% Upside | Upgrade to Pro+ | |
Pinestone Capital | Hong Kong | Financial | Investment Banking & Investment Services | -8.5% | HK$58.20M | -4.8x | -0.05 | HK$0.22 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
MGM China Holdings | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -9.5% | HK$41.12B | 9.1x | 0.03 | HK$10.82 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.5% Upside | Upgrade to Pro+ | |
Tong Tong AI Social | Hong Kong | Financial | Banking Services | -10.8% | HK$1.53B | 12.1x | 0.03 | HK$0.30 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Merchants China Direct | Hong Kong | Financial | Investment Banking & Investment Services | -11.4% | HK$2.02B | 170.2x | 1.54 | HK$13.26 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zhaoke Ophthalmology | Hong Kong | Healthcare | Pharmaceuticals | -13.2% | HK$764.59M | -3.1x | -0.06 | HK$1.39 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Emperor Capital | Hong Kong | Financial | Investment Banking & Investment Services | -14.8% | HK$370.75M | 5.5x | 0.04 | HK$0.05 | 3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Capital Estate | Hong Kong | Financial | Investment Banking & Investment Services | -15.2% | HK$64.13M | 11.3x | 0.1 | HK$0.33 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galaxy Entertainment Group | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -15.9% | HK$140.34B | 16.9x | 0.01 | HK$32.05 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.8% Upside | Upgrade to Pro+ | |
Melco Int Development | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -17.2% | HK$5.44B | -5.1x | -0.07 | HK$4.29 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.3% Upside | Upgrade to Pro+ | |
E Station Green Tech | Hong Kong | Consumer Cyclicals | Hotels & Entertainment Services | -17.5% | HK$17.04M | 0.3x | 0 | HK$0.25 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sirnaomics | Hong Kong | Healthcare | Biotechnology & Medical Research | -18.8% | HK$265.66M | -0.4x | -0.15 | HK$3.07 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Holly Futures Co | Hong Kong | Financial | Investment Banking & Investment Services | -19.1% | HK$2.81B | 114.2x | 1.23 | HK$2.77 | 8.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DT Capital | Hong Kong | Financial | Investment Holding Companies | -19.4% | HK$150.44M | -18.3x | -0.3 | HK$0.05 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Graphene | Hong Kong | Real Estate | Real Estate Operations | -23.9% | HK$381.16M | 20x | 0.44 | HK$0.06 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mabpharm | Hong Kong | Healthcare | Biotechnology & Medical Research | -24.3% | HK$1.05B | -5.9x | 0.75 | HK$0.25 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beigene | Hong Kong | Healthcare | Biotechnology & Medical Research | -25.7% | HK$12.58B | -0.3x | -1.4 | HK$118.20 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Remegen | Hong Kong | Healthcare | Biotechnology & Medical Research | -26.3% | HK$12.36B | -5.5x | 0.4 | HK$12.34 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ARTA TechFin | Hong Kong | Financial | Investment Banking & Investment Services | -26.5% | HK$778.39M | -19x | -0.32 | HK$0.04 | -5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CL | Hong Kong | Financial | Investment Banking & Investment Services | -32.2% | HK$101.20M | 4.2x | 0.02 | HK$0.05 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |